$26.97 -0.13 (-0.48%)
2/9/2010 4:00 PM

Salix Pharmaceuticals, Ltd. (SLXP)

CAPS Rating: 2 out of 5

A pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal diseases, which are those affecting the digestive tract.

Current Price $26.97 Mkt Cap $1.33B
Open $27.45 P/E Ratio 41.71
Prev. Close $27.10 Div. (Yield) N/A (N/A)
Daily Range $26.82 - $27.47 Volume 368,050
52-Wk Range $6.14 - $29.91 Avg. Daily Vol. 0

SLXP News and Commentary

Related News and Articles

Caps

How do you think SLXP will perform vs the S&P 500?

Add Stock to Watchlist

All Members

99 Outperform
29 Underperform
 

All-Star Members

39 Outperform
9 Underperform
 

Wall Street

7 Outperform
1 Underperform
 

Top SLXP Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

tenmiles (99.99)
Submitted December 28, 2007

Looks like time to go long Salix.

Large short position in company and they have had their way of late. At current $10 range, stock offers strong value - mid teen ROE, strong balance sheet and good growth prospects including potential… More

zzlangerhans (99.64)
Submitted March 19, 2009

Imagine, if you will, that it is December 3, 2008. Reeling from crushing blows to erstwhile blue chip financial and commodity stocks, you seek to change your fortune with speculative biotech investments. Some diligent research allows you to identify… More

SLXP VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about SLXP.

Recs

0
Member Avatar michaeltbryant (< 20) Submitted: 9/15/2009 2:35:40 AM : Outperform Start Price: $19.71 SLXP Score: +34.67

Near term catalyst - Positive results

Recs

0
Member Avatar LexTNZorro (74.02) Submitted: 5/9/2009 5:20:59 PM : Outperform Start Price: $9.90 SLXP Score: +154.28

http://seekingalpha.com/article/136379-fda-clinical-trial-calendar-updates-wye-svnt-amrn-isis-slxp-somx?source=feed

Recs

0
Member Avatar zzlangerhans (99.64) Submitted: 5/8/2009 3:18:26 PM : Underperform Start Price: $10.00 SLXP Score: -153.08

I'm nervous that Celldex will slip below the 100M threshold and I'll never be able to catch them again. I'm pretty confident they're headed nowhere so even if I eat dirt on this in the short-term the pick will eventually pay off and I'll be score leader. Here's my prior underperform pitch - nothing has changed:

Celldex has a lot of potential on paper but does not inspire confidence with their behavior. Whether it's the strange merger between a vaccine developer and an oncology biotech, the confusing name changes, or data mining failed trials, they have labeled themselves in my mind as a long-term failure. The most recent source of irritation is the decision to change a planned controlled phase IIb/III study of CDX-110 to a single-arm phase II study, apparently because patients were withdrawing from the study after being randomized to the control arm. Admittedly I haven't looked into this sufficiently to determine exactly how patients knew they were in the control arm of a supposedly randomized controlled study, but I am amazed at how the company appears to have blithely set themselves back an entire level of development. The market doesn't seem to care much either, rewarding the stock with a double.

Leaderboard

Find the members with the highest scoring picks in SLXP.

Score Leader

yodabuddha

yodabuddha (38.48) Score: +382.75

The Score Leader is the member with the highest score across all their picks in SLXP.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score Commentary
yodabuddha 38.48 3/11/2008 Outperform 1Y $5.76 +368.23% -14.52% +382.75
schwah 53.26 2/25/2008 Outperform 1Y $6.32 +326.74% -17.56% +344.30
garyjcarter 86.15 3/25/2008 Outperform 1Y $6.48 +316.20% -17.55% +333.75
eibe 90.39 2/12/2008 Outperform 3Y $6.54 +312.39% -17.51% +329.90
hmlamo 64.74 4/14/2008 Outperform 1Y $6.53 +313.02% -16.44% +329.46
Foxyprox 93.80 2/13/2008 Outperform 3Y $6.58 +309.88% -17.84% +327.72 1 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. hayrettin 77.58 3/24/2008 12/23/2008 Outperform 5Y $6.60 +308.64% -16.59% +325.23
StockLeader 77.27 3/20/2008 Outperform 3M $6.60 +308.64% -16.24% +324.87 1 Comment
dvangelic 51.95 4/10/2008 Outperform 1Y $6.68 +303.74% -18.14% +321.89
goodbar2k 98.98 2/27/2008 Outperform 1Y $6.75 +299.56% -18.77% +318.33

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer < 20 1/8/2010 Underperform 3W $27.99 -3.64% -6.42% -2.77
TrackWedbush 66.12 9/23/2009 Outperform NS $20.73 +30.10% -0.09% +30.19
TrackMerriman < 20 8/12/2009 Outperform NS $12.59 +114.22% +8.21% +106.01
TrackPiperJaff 85.79 7/7/2009 Outperform NS $9.91 +172.15% +20.09% +152.06
TrackCreditSuiss 93.62 6/15/2009 Outperform NS $10.68 +152.53% +15.30% +137.22
TrackRothCapital 80.39 6/5/2009 Outperform NS $11.10 +142.97% +13.42% +129.55
TrackCarisandCo 86.28 3/31/2009 Outperform NS $9.38 +187.53% +36.17% +151.36
TrackZacks 62.21 10/20/2008 Underperform 3M $7.47 +47.12% -13.16% -60.28 4/11/2009 @ $10.99 1 Comment
TrackZacks 62.21 3/7/2008 Underperform 3M $6.05 +23.47% -23.82% -47.29 10/20/2008 @ $7.47 1 Comment
TrackPiperJaff 85.79 12/31/2007 Underperform NS $8.24 +20.27% -39.20% -59.47 7/7/2009 @ $9.91
TrackSoros 82.58 9/30/2007 Outperform NS $12.42 +117.15% -26.38% +143.52 1 Comment
TrackSchneider < 20 9/30/2007 Outperform NS $12.42 -45.49% -9.30% -36.19 5/27/2008 @ $6.77 1 Comment
TrackRothCapital 80.39 5/9/2007 Outperform NS $13.05 -42.84% -16.03% -26.80 8/5/2008 @ $7.46

Featured Broker Partners